首页 | 本学科首页   官方微博 | 高级检索  
     


Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial
Affiliation:1. Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA;2. Medical Department II, Grosshadern, University Munich, Munich, Germany;3. Metabolic Leader, LLC, Scarborough, PA, USA;4. University of Pennsylvania, Philadelphia, PA, USA;5. Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA;6. Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany;7. Apheresis Centrum Rostock, Rostock, Germany;8. Mayo Clinic, Rochester, MN, USA;9. Charite—Universitätsmedizin Berlin–Campus Virchow–Klinikum, Berlin, Germany;10. Cardiology, Hartford Hospital, Hartford, CT, USA;11. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany;12. Medical Department, Sanofi–Aventis Deutschland GmbH, Berlin, Germany;13. Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA;14. Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Abstract:
Keywords:Alirocumab  Familial hypercholesterolemia  Low-density lipoprotein cholesterol  Monoclonal antibody  Proprotein convertase subtilisin/kexin type 9
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号